Hims & Hers stock falls 10% on revenue miss

Hims & Hers stock falls 10% on revenue miss


The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. 

Gabby Jones | Bloomberg | Getty Images

Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Earnings per share: 17 cents adjusted vs. 15 cents
  • Revenue: $544.8 million vs. $552 million

Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.

For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million.

Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.

Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It’s legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. 

In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.

Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount.

Hims & Hers will host its quarterly call with investors at 5 p.m. ET.

Stock Chart IconStock chart icon

hide content

YTD chart of Hims & Hers Health.

–CNBC’s Annika Kim Constantino contributed to this report



Source

India calls out EU and U.S.’ trade with Russia after Trump threatens steeper tariffs on New Delhi
World

India calls out EU and U.S.’ trade with Russia after Trump threatens steeper tariffs on New Delhi

Students from Gurukul School of Art, carry a poster of Prime Minister of India Narendra Modi and U.S. President Donald Trump on India outside their school. U.S. President Donald Trump imposed a 25% tariff on India along with penalties for buying oil and military equipments from Russia. Sopa Images | Lightrocket | Getty Images India […]

Read More
Asia markets open higher after Trump vows to significantly raise tariffs on India
World

Asia markets open higher after Trump vows to significantly raise tariffs on India

Opening calls Happy Tuesday from Singapore. Asia markets are poised for a mixed open. Australia’s S&P/ASX 200 was set to start the day higher with futures tied to the benchmark at 8,701, compared with its last close of 8,663.70. Japan’s benchmark Nikkei 225 was set to open higher, with the futures contract in Osaka last traded at 40,610 against […]

Read More
S&P 500 futures inch higher after benchmark snaps losing streak, Palantir pops on earnings: Live updates
World

S&P 500 futures inch higher after benchmark snaps losing streak, Palantir pops on earnings: Live updates

Traders work at the New York Stock Exchange on July 30, 2025. NYSE Stock futures were slightly higher on Monday night, following Wall Street’s rebound, as investors followed the latest batch of corporate earnings. Dow Jones Industrial Average futures added 54 points, or 0.1%. S&P 500 futures and Nasdaq 100 futures each also added 0.1%. […]

Read More